Gland Pharma (NSE:GLAND) EPS (Basic) : ₹46.90 (TTM As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Gland Pharma EPS (Basic)?

Gland Pharma's basic earnings per share (Basic EPS) for the three months ended in Mar. 2024 was ₹11.68. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2024 was ₹46.90.

Gland Pharma's EPS (Diluted) for the three months ended in Mar. 2024 was ₹11.68. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was ₹46.89.

Gland Pharma's EPS without NRI for the three months ended in Mar. 2024 was ₹11.68. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2024 was 46.89.

During the past 12 months, Gland Pharma's average EPS without NRIGrowth Rate was -6.20% per year. During the past 3 years, the average EPS without NRI Growth Rate was -9.40% per year. During the past 5 years, the average EPS without NRI Growth Rate was 8.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 7 years, Gland Pharma's highest 3-Year average EPS without NRI Growth Rate was 47.30% per year. The lowest was -9.40% per year. And the median was 20.10% per year.

Gland Pharma EPS (Basic) Historical Data

The historical data trend for Gland Pharma's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gland Pharma EPS (Basic) Chart

Gland Pharma Annual Data

Trend

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

EPS (Basic)

Get a 7-Day Free Trial

47.33

63.07

73.81

47.44

46.90

Gland Pharma Quarterly Data
	Mar19	Jun19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EPS (Basic)	Get a 7-Day Free Trial															4.77	11.79	11.78	11.65	11.68

Gland Pharma EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Gland Pharma's Basic EPS for the fiscal year that ended in Mar. 2024 is calculated as

Basic EPS (A: Mar. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(7724.6	-	0)	/	164.704
	=	46.90

Gland Pharma's Basic EPS for the quarter that ended in Mar. 2024 is calculated as

Basic EPS (Q: Mar. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(1924.2	-	0)	/	164.743
	=	11.68

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹46.90

Gland Pharma (NSE:GLAND) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Gland Pharma EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Gland Pharma's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Gland Pharma (NSE:GLAND) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gland Pharma Ltd (NSE:GLAND) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

543245:India

Address

Plot No. 11 and 84, TSIIC Phase: IV, Pashamylaram (V), Patancheru (M), Sangareddy District, Hyderabad, TG, IND, 502307

Website

https://www.glandpharma.com

Gland Pharma Ltd is engaged in the development, manufacturing, and marketing of complex injectables. The company's key molecules include Heparin Sodium Injection, Enoxaparin Sodium Injection, Rocuronium Bromide Injection, Daptomycin Injection, among others. Further, the group is involved in vast range of therapeutic categories that include Anti-Infectives, Anesthetics, Anti-Coagulants and their Antidotes, Anti-Malarial, Cardiology and more - to Hormones and related Drugs, Fertility Supplements and Gnrh Agonists and Antagonists. Geographically, it derives a majority of revenue from the USA.

Gland Pharma (NSE:GLAND) Headlines

No Headlines